company mission
The mission barely moves across these three snapshots. In July 2020, March 2021, and January 2022, the company says the same basic thing: drug discovery should run on three linked pieces, human iPSC-derived cells, tissue-specific biosystems, and AI-enabled data analytics. The promise stays consistent too: build human-relevant models, measure them under more physiological conditions, and turn the resulting signals into better discovery and safety decisions. What changes is mostly emphasis, not direction. The 2020 version talks about accelerating discovery and improving disease modeling and safety screening. By 2021 and 2022, the wording leans harder into maturity and disease relevance of the cell models, physiological mechanical conditions in vitro, and phenotypic screening insights. That looks like message refinement, not a strategic pivot. Evidence is thin because the record here covers only three website snapshots over about 18 months, and all three repeat near-identical language. Based on this set alone, the clearest reading is stability: the company kept presenting itself as a platform that combines stem-cell-derived human biology, measurement systems, and AI analysis to speed therapeutic discovery.